ENTRAYNIA Trademark

Trademark Overview


On Wednesday, October 22, 2025, a trademark application was filed for ENTRAYNIA with the United States Patent and Trademark Office. The USPTO has given the ENTRAYNIA trademark a serial number of 99457144. The federal status of this trademark filing is NEW APPLICATION - RECORD INITIALIZED NOT ASSIGNED TO EXAMINER as of Wednesday, October 22, 2025. This trademark is owned by Vanda Pharmaceuticals Inc.. The ENTRAYNIA trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the treatment of viral diseases; Pharmaceutical preparations for the treatment of viral infections; Pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; Pharmaceutical preparations for the treatment of Non-24-Hour Sleep-Wake Disorder; Pharmaceutical preparations for the treatment of circadian rhythm diseases and disorders; Pharmaceutical preparations for the treatment of jet lag disorder; Pharmaceutical preparations for the treatment of Smith-Magenis Syndrome; Pharmaceutical preparations for the treatment of nighttime sleep disturbances in patients with Smith-Magenis Syndrome (SMS); Pharmaceutical preparations for the treatment of Delayed Sleep Phase Disorder; Pharmaceutical preparations for the treatment of bipolar disorder; Pharmaceutical preparations for the treatment of schizophrenia; Pharmaceutical preparations for the treatment of atopic dermatitis; Pharmaceutical preparations for the treatment of pruritus; Ph...
entraynia

General Information


Serial Number99457144
Word MarkENTRAYNIA
Filing DateWednesday, October 22, 2025
Status630 - NEW APPLICATION - RECORD INITIALIZED NOT ASSIGNED TO EXAMINER
Status DateWednesday, October 22, 2025
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements


Goods and ServicesPharmaceutical preparations for the treatment of viral diseases; Pharmaceutical preparations for the treatment of viral infections; Pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; Pharmaceutical preparations for the treatment of Non-24-Hour Sleep-Wake Disorder; Pharmaceutical preparations for the treatment of circadian rhythm diseases and disorders; Pharmaceutical preparations for the treatment of jet lag disorder; Pharmaceutical preparations for the treatment of Smith-Magenis Syndrome; Pharmaceutical preparations for the treatment of nighttime sleep disturbances in patients with Smith-Magenis Syndrome (SMS); Pharmaceutical preparations for the treatment of Delayed Sleep Phase Disorder; Pharmaceutical preparations for the treatment of bipolar disorder; Pharmaceutical preparations for the treatment of schizophrenia; Pharmaceutical preparations for the treatment of atopic dermatitis; Pharmaceutical preparations for the treatment of pruritus; Pharmaceutical preparations for the treatment of gastroparesis; Pharmaceutical preparations for the treatment of hematologic malignancies; Pharmaceutical preparations for the treatment of fatigue; Pharmaceutical preparations for the treatment of narcolepsy; Pharmaceutical preparations for the treatment of levodopa-induced dyskinesias in Parkinson's Disease; Pharmaceutical preparations for the treatment of viral pneumonia; Pharmaceutical preparations for the treatment of social anxiety disorder and social anxiety disorder performance-only subtype; Pharmaceutical preparations for the treatment of respiratory distress, acute respiratory distress syndrome, and inflammatory lung injury; Pharmaceutical preparations for the treatment of cancer; Pharmaceutical preparations for the treatment of multiple myeloma; Pharmaceutical preparations and substances for the treatment of psychiatric diseases and disorders; Pharmaceutical preparations for the treatment and prevention of motion sickness; Pharmaceutical preparations for use in dermatology; Pharmaceutical preparations for treating skin disorders; Pharmaceutical preparations for treating epidermal problems; Pharmaceutical preparations for the central nervous system; Pharmaceutical preparations acting on the central nervous system; Pharmaceutical preparations, namely, antivirals; Pharmaceutical preparations for the reduction of cravings for alcohol, food, nicotine, opioids, or opiates; Pharmaceutical preparations for facilitating emergence from general anesthesia; Pharmaceutical preparations for improving cognition; Pharmaceutical preparations for the treatment of gastric motility and gastric emptying disorders

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateWednesday, October 22, 2025
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameVanda Pharmaceuticals Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressWashington, DC 20037

Trademark Events


Event DateEvent Description
Wednesday, October 22, 2025NEW APPLICATION ENTERED
Wednesday, October 22, 2025NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Wednesday, October 22, 2025APPLICATION FILING RECEIPT MAILED